First, peptide antigens frequently encountered in certain tumor types, such as Melan-A, gp100 peptide, and HMB-45 in melanoma, were isolated and injected into patients, so that they might be absorbed by DCs, which would, in turn, set off the lymphocytic immune response. This evidence concerns the gene PMEL and neoplasm.